Search results
Results from the WOW.Com Content Network
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics [3] for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. [4]
(Reuters) -Alnylam Pharmaceuticals said on Friday it plans to appeal a ruling by the U.S. District Court for the District of Delaware on two patents asserted against Moderna for the latter's COVID ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (NAS: ALNY) , a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with an RNAi ...
Alnylam has also formed Alnylam Biotherapeutics, a division of the company focused on the development of RNAi technologies for applications in biologics manufacturing, including recombinant ...
The company's shares have climbed more than 70% since it disclosed early results of the late-stage study of the drug, vutrisiran, in June. Vutrisiran was tested in patients with transthyretin ...
Alnylam has closed on its previously announced acquisition of Merck's RNAi business, Sirna Therapeutics. That deal could prove one of the best buys in RNAi since Arrowhead walked away with Roche's ...
For premium support please call: 800-290-4726 more ways to reach us
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.